Salix Pharmaceuticals competitors

I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM. I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors. I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since August 2006. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.

Mr. Patel’s lifelong drive and constant desire to discover what’s next has carried Amneal Pharmaceuticals from humble beginnings to an emerging global presence. Patel is the recipient of several industry honors including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award® and supports various philanthropic and charitable causes both in the US and abroad. Patel and his wife, Priti Patel, established the Niswarth Children Foundation in 2013, with the goal of bringing fresh water, sanitation, sustenance, and education to one million underprivileged children. Patel received his bachelor’s degree in commerce from H.A. College of Commerce, India, and his Bachelor of Science in business administration from New Jersey City University. He also received an honorary degree of doctor of humane letters from New Jersey City University in recognition of his efforts to serve others and help them transform their lives. Patel serves on the boards of the Generic Pharmaceutical Association, the Art of Living Foundation, the New Jersey City University Foundation, and the Family Reach Foundation.

Antony Loebel is a Chief Medical Officer at Sunovion Pharmaceuticals Inc and is based in New York, New York.